Jim Hoyes Ceo
Jim Hoyes is a proven, effective leader with strong commercial results and broad biopharmaceutical experience across multiple therapeutic areas and specialty spaces.
Prior to joining Alitair as our CEO, Jim has had a long and successful career in the pharmaceutical industry. He founded and led the consulting firm RxC to a global presence and consulted with many leading pharmaceutical companies including: J&J and Novartis.
Prior founding RxC Jim was President and Head of US operations at EMD Serono, Inc. from 2011 to 2013. As President of EMD Serono, he developed and executed the Merck KGaA business plans for the US Market. He had full P/L responsibility for the US commercial business and grew the business from $600M in sales to $2 billion in sales. Jim averaged double-digit growth at EMD Serono in his tenure.
His areas of direct responsibility include Medical, Regulatory and BD; indirect responsibility for US activities of Global Research & Development based in Billerica, MA as Managing Director of US. During his tenure as President, Jim built and developed a high performing Executive Leadership Team. He also served as the key member of the Merck Serono Global Operations Committee.
Jim successfully executed General Manager and Managing Director responsibilities. He was also responsible for operations in Rockland MA, Billerica MA and Washington DC.
Jim was also responsible for implementing the US portion of Merck’s “Fit for 2018” program to improve profitability. He also successfully implemented a Corporate Integrity Agreement; Chief Compliance Officer was a direct report. As lead US executive, he served as Merck’s representative on industry trade groups (PhRMA, BIO) and with government officials in MA and Washington, DC.
Jim Hoyes has a long track record of creating strategies and driving exceptional performance in the life sciences sector. In addition to providing advisory services to clients, Jim focuses on corporate development initiatives in the life sciences sector and the implementation of key strategic initiatives designed to scale up the firm’s global operations. Jim has deep expertise in all areas of corporate development and commercialization of pharmaceutical and biotechnology products. He has led a number of financial transactions including licensing and M&A deals.
Jim is on the board of MassBIO and has served on the boards of PhRMA and BIO. Jim is also involved with the boards of several non-profit community service organizations in the greater Boston area. Jim received a B.S. in Biology from Penn State University